Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06087757 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clemastine Treatment in Individuals With Williams Syndrome

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 6, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Phase: Phase 3 to Phase 2v4 Show 4 more changesShow less
    • Primary completion date: Dec 2024 to May 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 2025 to Jul 2026
    • Site details revised at 2 of 2 sites
  2. Start date changed from estimate of Jan 2024 to Apr 1, 2024v3
  3. Start date: Oct 2023 to Jan 2024v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study explores the neurobiological etiology of Williams syndrome and potential therapeutic targets for associated social, motor, and cognitive abnormalities. The main translational objective will be to test the effectiveness of Clemasntine on neurocognitive and other associated abnormalities in individuals with Williams syndrome.
Trial Details
NCT Number NCT06087757
Lead Sponsor Sheba Medical Center
Collaborators: Tel Aviv University
Conditions
(from sponsor)		 Williams Syndrome
Related terms Williams Syndrome
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov